| Catalog No. |
TD-HY257156 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG4-kappa |
| Expression system |
Mammalian Cells |
| Species |
Human |
| Clonality |
Monoclonal |
| Target |
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| Endotoxin level |
Please contact with the lab for this information. |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P11836 & P07766 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names |
Bispecific, REGN-1979, CAS: 1801338-64-6 |
| Background |
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research. |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |